Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 122

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 4
Chunk 122
---

In another study conducted by the Kimron Veterinary
Institute’s Department of Toxicology, a toxicological evaluation was performed where acute and subacute toxicity was evaluated on
rats as well as in-vitro cytotoxic and mutagenic effects. The study involved 48 subjects, with 18 rats testing acute toxicity at three
different dosages (10 mg/kg, 100 mg/kg and 1,000 mg/kg per day) and 30 rats testing subacute toxicity for five consecutive days at three
different dosages (10 mg/kg, 30 mg/kg and 90 mg/kg per day). Firstly, it was determined that acute, single oral administration of MEAI
to rats at a dose level of 10 mg/kg was well tolerated. In the 100 mg/kg MEAI group, all rats displayed transient adverse clinical signs
that lasted for one day post dosing. Major adverse clinical signs observed: tremor, straub tail, dyspnea, piloerection, hunched back,
decreased motor activity and salivation. No gross pathology abnormalities were detected in the groups treated with 10 mg/kg and 100 mg/kg
MEAI at the scheduled termination day. In the 1,000 MEAI mg/kg group, all animals died within 30 - 120 minutes post dosing. Tremors,
Straub tail, dyspnea, piloerection, decreased motor activity and convulsions were the major adverse clinical signs observed in these animals
before death. Enlarged lungs, whitish spleen and surface white spots on the liver were the only gross pathology abnormalities observed
postmortem. Later, it was determined that sub-acute, five-day oral administration of MEAI to rats at dose levels of 10 mg/kg and 30 mg/kg
were well tolerated and did not cause any significant adverse clinical effects. In the 90 mg/kg group, all rats displayed transient adverse
clinical signs that lasted for five days during dosing. These adverse clinical signs were resolved spontaneously on the next day. It seems
that the adverse clinical signs were more severe after the first dosing and less severe after the third dosing, as if the animals developed
some kind of tolerance. The major adverse clinical signs observed included: on day 1, tremors, straub tail, dyspnea, piloerection, decreased
motor activity, lacrimation, peri nasal staining and salivation; on days 2 and 3, dyspnea